Bright Peak Therapeutics Announces $107 Million Series B Financing and Expanded Board of Directors

--Proceeds to advance company’s pipeline of next-generation cytokine immunotherapies----Laura Shawver, Christine Siu join as independent directors-- BASEL, Switzerland and SAN DIEGO, Calif., June 10, 2021 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a biotechnology company developing next-generation cytokine immunotherapies to treat cancer and autoimmune disease, today announced that it raised $107 million in a Series B financing. The round was led by RA Capital, with participation by founding

Related Keywords

,Yahoo ,Versant Ventures ,Autoimmune Disease ,Qatar Investment Authority ,Christine Siu ,Bright Peak ,Fidelity Management Research Company ,Ala Capital ,Proprietary Technology ,Seriesb Financing ,Autoimmune Diseases ,Biotechnology Company ,Mmunotherapies ,Herapeutics ,யாகூ ,பல்துறை முயற்சிகள் ,